Merck Says European Commission Approved Two New Indications For KEYTRUDA (Pembrolizumab), Its Anti-PD-1 Therapy, In Gynecologic Cancers
Portfolio Pulse from Benzinga Newsdesk
Merck announced that the European Commission has approved two new indications for KEYTRUDA, its anti-PD-1 therapy, in gynecologic cancers. This includes the first EU approval for KEYTRUDA combined with chemotherapy for patients with primary advanced or recurrent endometrial carcinoma, regardless of mismatch repair status.
October 24, 2024 | 10:47 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Merck's KEYTRUDA has received EU approval for two new indications in gynecologic cancers, including a first for its combination with chemotherapy in endometrial carcinoma.
The approval of new indications for KEYTRUDA in the EU is a significant development for Merck, as it expands the use of its anti-PD-1 therapy in gynecologic cancers. This could lead to increased sales and market share in the oncology sector, positively impacting Merck's stock price.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90